HSD17B13 and hepatocellular carcinoma: In 110,761 individuals from the Danish general population and 334,691 individuals from the UK Biobank, the combination of PNPLA3, transmembrane 6, superfamily member 2 (TM6SF2) and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) is associated with an up to 12-fold higher risk of developing cirrhosis and an up to 29-fold higher risk of developing HCC [64].